Literature DB >> 29771332

Mechanisms of skeletal muscle wasting in a mouse model for myotonic dystrophy type 1.

Ginny R Morriss1, Kimal Rajapakshe2, Shixia Huang2,3, Cristian Coarfa2, Thomas A Cooper1,2,4.   

Abstract

Myotonic dystrophy type 1 (DM1) is a multi-systemic disease resulting in severe muscle weakening and wasting. DM1 is caused by expansion of CTG repeats in the 3' untranslated region of the dystrophia myotonica protein kinase (DMPK) gene. We have developed an inducible, skeletal muscle-specific mouse model of DM1 (CUG960) that expresses 960 CUG repeat-expressing animals (CUG960) in the context of human DMPK exons 11-15. CUG960 RNA-expressing mice induced at postnatal day 1, as well as adult-onset animals, show clear, measurable muscle wasting accompanied by severe histological defects including central myonuclei, reduced fiber cross-sectional area, increased percentage of oxidative myofibers, the presence of nuclear RNA foci that colocalize with Mbnl1 protein, and increased Celf1 protein in severely affected muscles. Importantly, muscle loss, histological abnormalities and RNA foci are reversible, demonstrating recovery upon removal of toxic RNA. RNA-seq and protein array analysis indicate that the balance between anabolic and catabolic pathways that normally regulate muscle mass may be disrupted by deregulation of platelet derived growth factor receptor β signaling and the PI3K/AKT pathways, along with prolonged activation of AMP-activated protein kinase α signaling. Similar changes were detected in DM1 skeletal muscle compared with unaffected controls. The mouse model presented in this paper shows progressive skeletal muscle wasting and has been used to identify potential molecular mechanisms underlying skeletal muscle loss. The reversibility of the phenotype establishes a baseline response for testing therapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29771332      PMCID: PMC6077786          DOI: 10.1093/hmg/ddy192

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  84 in total

1.  Balancing muscle hypertrophy and atrophy.

Authors:  Eric P Hoffman; Gustavo A Nader
Journal:  Nat Med       Date:  2004-06       Impact factor: 53.440

Review 2.  Myotonic dystrophy mouse models: towards rational therapy development.

Authors:  Mário Gomes-Pereira; Thomas A Cooper; Geneviève Gourdon
Journal:  Trends Mol Med       Date:  2011-07-02       Impact factor: 11.951

3.  AMP-activated protein kinase induces a p53-dependent metabolic checkpoint.

Authors:  Russell G Jones; David R Plas; Sara Kubek; Monica Buzzai; James Mu; Yang Xu; Morris J Birnbaum; Craig B Thompson
Journal:  Mol Cell       Date:  2005-04-29       Impact factor: 17.970

4.  Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy.

Authors:  R S Savkur; A V Philips; T A Cooper
Journal:  Nat Genet       Date:  2001-09       Impact factor: 38.330

5.  Reversal of RNA missplicing and myotonia after muscleblind overexpression in a mouse poly(CUG) model for myotonic dystrophy.

Authors:  Rahul N Kanadia; Jihae Shin; Yuan Yuan; Stuart G Beattie; Thurman M Wheeler; Charles A Thornton; Maurice S Swanson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-24       Impact factor: 11.205

Review 6.  The AMPK signalling pathway coordinates cell growth, autophagy and metabolism.

Authors:  Maria M Mihaylova; Reuben J Shaw
Journal:  Nat Cell Biol       Date:  2011-09-02       Impact factor: 28.824

7.  Transcriptome-wide regulation of pre-mRNA splicing and mRNA localization by muscleblind proteins.

Authors:  Eric T Wang; Neal A L Cody; Sonali Jog; Michela Biancolella; Thomas T Wang; Daniel J Treacy; Shujun Luo; Gary P Schroth; David E Housman; Sita Reddy; Eric Lécuyer; Christopher B Burge
Journal:  Cell       Date:  2012-08-17       Impact factor: 41.582

8.  HTSeq--a Python framework to work with high-throughput sequencing data.

Authors:  Simon Anders; Paul Theodor Pyl; Wolfgang Huber
Journal:  Bioinformatics       Date:  2014-09-25       Impact factor: 6.937

9.  How many biological replicates are needed in an RNA-seq experiment and which differential expression tool should you use?

Authors:  Nicholas J Schurch; Pietá Schofield; Marek Gierliński; Christian Cole; Alexander Sherstnev; Vijender Singh; Nicola Wrobel; Karim Gharbi; Gordon G Simpson; Tom Owen-Hughes; Mark Blaxter; Geoffrey J Barton
Journal:  RNA       Date:  2016-03-28       Impact factor: 4.942

10.  Foci of trinucleotide repeat transcripts in nuclei of myotonic dystrophy cells and tissues.

Authors:  K L Taneja; M McCurrach; M Schalling; D Housman; R H Singer
Journal:  J Cell Biol       Date:  1995-03       Impact factor: 10.539

View more
  11 in total

1.  Intrinsically cell-penetrating multivalent and multitargeting ligands for myotonic dystrophy type 1.

Authors:  JuYeon Lee; Yugang Bai; Ullas V Chembazhi; Shaohong Peng; Kevin Yum; Long M Luu; Lauren D Hagler; Julio F Serrano; H Y Edwin Chan; Auinash Kalsotra; Steven C Zimmerman
Journal:  Proc Natl Acad Sci U S A       Date:  2019-04-11       Impact factor: 11.205

2.  Overexpression of Staufen1 in DM1 mouse skeletal muscle exacerbates dystrophic and atrophic features.

Authors:  Tara E Crawford Parks; Kristen A Marcellus; Christine Péladeau; Bernard J Jasmin; Aymeric Ravel-Chapuis
Journal:  Hum Mol Genet       Date:  2020-08-03       Impact factor: 6.150

Review 3.  Molecular Therapies for Myotonic Dystrophy Type 1: From Small Drugs to Gene Editing.

Authors:  Mariapaola Izzo; Jonathan Battistini; Claudia Provenzano; Fabio Martelli; Beatrice Cardinali; Germana Falcone
Journal:  Int J Mol Sci       Date:  2022-04-21       Impact factor: 6.208

4.  Systemic therapy in an RNA toxicity mouse model with an antisense oligonucleotide therapy targeting a non-CUG sequence within the DMPK 3'UTR RNA.

Authors:  Ramesh S Yadava; Qing Yu; Mahua Mandal; Frank Rigo; C Frank Bennett; Mani S Mahadevan
Journal:  Hum Mol Genet       Date:  2020-06-03       Impact factor: 6.150

5.  Transcriptome alterations in myotonic dystrophy skeletal muscle and heart.

Authors:  Eric T Wang; Daniel Treacy; Katy Eichinger; Adam Struck; Joseph Estabrook; Hailey Olafson; Thomas T Wang; Kirti Bhatt; Tony Westbrook; Sam Sedehizadeh; Amanda Ward; John Day; David Brook; J Andrew Berglund; Thomas Cooper; David Housman; Charles Thornton; Christopher Burge
Journal:  Hum Mol Genet       Date:  2019-04-15       Impact factor: 6.150

6.  Reverse-Phase Protein Array: Technology, Application, Data Processing, and Integration.

Authors:  Cristian Coarfa; Sandra L Grimm; Kimal Rajapakshe; Dimuthu Perera; Hsin-Yi Lu; Xuan Wang; Kurt R Christensen; Qianxing Mo; Dean P Edwards; Shixia Huang
Journal:  J Biomol Tech       Date:  2021-04

Review 7.  Human iPSC Models to Study Orphan Diseases: Muscular Dystrophies.

Authors:  Guangbin Xia; Naohiro Terada; Tetsuo Ashizawa
Journal:  Curr Stem Cell Rep       Date:  2018-10-04

Review 8.  Correction of RNA-Binding Protein CUGBP1 and GSK3β Signaling as Therapeutic Approach for Congenital and Adult Myotonic Dystrophy Type 1.

Authors:  Lubov Timchenko
Journal:  Int J Mol Sci       Date:  2019-12-21       Impact factor: 5.923

9.  Reversible cardiac disease features in an inducible CUG repeat RNA-expressing mouse model of myotonic dystrophy.

Authors:  Ashish N Rao; Hannah M Campbell; Xiangnan Guan; Tarah A Word; Xander Ht Wehrens; Zheng Xia; Thomas A Cooper
Journal:  JCI Insight       Date:  2021-03-08

10.  Modeling muscle regeneration in RNA toxicity mice.

Authors:  Ramesh S Yadava; Mahua Mandal; Jack M Giese; Frank Rigo; C Frank Bennett; Mani S Mahadevan
Journal:  Hum Mol Genet       Date:  2021-06-09       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.